|Articles|October 12, 2020
Assessing Multiple Critical Quality Attributes of Monoclonal Antibody and Comparability Assessments
Author(s)Agilent Technologies
Discover how LC/MS peptide mapping can be used to characterize and quantify different monoclonal antibody (mAb) critical quality attributes (CQAs).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Formulation Strategies, Tech Advances, Challenges, and Considerations in Novel Drug Delivery
2
FAQ: What You Need to Know About How Industry is Tackling CGT Bottlenecks
3
Drug Digest: Biopharma Landscape Evolves Through Strategic Alliances and Technology Integration
4
BioPharm Weekly News Roundup—Week of Nov. 24, 2025
5
